A Medical Device Daily
Kofax (Irvine, California, a provider of Intelligent Capture & Exchange solutions, reported it is providing the leading regulator of health and social care services in England with software to automatically receive, exchange and output information from more than 3 million medical records annually. The value of the contract to Kofax is more than $200,000.
Kofax Communication Server will allow the agency to receive documents from social workers, field representatives and agency staff via fax for processing and thereby consolidate and streamline its communications into a centralized, automated system. This will reduce labor-intensive, mistake- prone manual processing tasks and enable faster processing times, significant cost savings and better compliance with stringent health information privacy and security mandates. The company said.
"This sale demonstrates our ability to help reduce labor-intensive tasks and take costs out of their operations," said Alan Kerr, Executive VP of Field Operations at Kofax. "Processing medical records efficiently, accurately and securely plays a key role in helping healthcare organizations improve productivity and generate a fast return on their investment."
Repel-CV garners Russian approval
SyntheMed (Iselin, New Jersey), a biomaterials company engaged in the development of anti-adhesion products, reported that Repel-CV, the company's bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery.
The product will be marketed throughout Russia by Cardiomedics, a distributor of cardiac surgery products.
Repel-CV is FDA approved for use in pediatric cardiac surgery patients and is marketed in the U.S. through a direct sales force. It also has CE mark approval for use in all cardiac surgery patients and is marketed in the European Union and certain other international countries through a network of independent distributors.
Reple-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions (scar tissue) that form between the surface of the heart and opposing tissue surfaces following the surgical procedure. It is designed to perform the therapeutic task and then degrade so that it is cleared from the body.